In vitro activity of ciprofloxacin against clinical isolates of Chlamydia trachomatis.
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002692:Chlamydia trachomatis / Q000187:drug effects*; D002939:Ciprofloxacin; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008826:Microbial Sensitivity Tests; D009268:Nalidixic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D015242:Ofloxacin; D010078:Oxazines / Q000494:pharmacology; D015366:Pefloxacin; D011804:Quinolines / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D010078:Oxazines; D011804:Quinolines; D015366:Pefloxacin; D009268:Nalidixic Acid; D002939:Ciprofloxacin; D015242:Ofloxacin